Eliseo Salinas
Chief Tech/Sci/R&D Officer at Phoenixus AG
Profile
Dr. Eliseo O. Salinas, MD, is a Chief Research & Development Officer at Passage Bio, Inc. and a President-Research & Development at Phoenixus AG. He is on the Board of Directors at Fortuna Fix Ltd. and ViroChem Pharma, Inc. Dr. Salinas was previously employed as a Chief Scientific Officer & Senior Vice President by ACADIA Pharmaceuticals, Inc., a Chief Medical Officer by New World Laboratories, a President & Chief Scientific Officer by Camp Nine, Inc., a President & Chief Scientific Officer by Relmada Therapeutics, Inc., a President & Chief Scientific Officer by Relmada Therapeutics, Inc. /Old/, an Executive VP, Head-Research & Development by StemCells, Inc., a Chief Medical Officer & Executive Vice President by Elan Corp. Plc, a Chief Medical Officer & Head-Development by Elan Pharmaceuticals, Inc., a Chief Medical Officer, SVP-Research & Development by Adolor Corp., a Chief Scientific Officer by Shire Acquisition, Inc., a Chief Scientific Officer, Executive VP-R&D by Shire Plc /Old/, a VP-Regional Clinical Research & Development by Wyeth Research, a Manager-International Project by Synthélabo SA, a President-Research & Development by Vyera Pharmaceuticals LLC, a Vice President-Clinical Research & Development by Wyeth Corp., and a Vice President-Research by Wyeth-Ayerst Research. He received his doctorate degree from Universidad de Buenos Aires.
Eliseo Salinas active positions
Companies | Position | Start |
---|---|---|
Phoenixus AG
Phoenixus AG Pharmaceuticals: MajorHealth Technology Phoenixus AG operates as a research-based pharmaceutical company. It develops and commercializes treatments for diseases and conditions with limited or no treatment options. The firm's products include Daraprim and Vecamyl. The company was founded by Martin Shkreli on February 24, 2015 and is headquartered in Baar, Switzerland. | Chief Tech/Sci/R&D Officer | - |
Fortuna Fix Ltd.
Fortuna Fix Ltd. Pharmaceuticals: MajorHealth Technology Fortuna Fix Ltd. engages in the regenerative medicine company with a patented direct cell reprogramming technology platform and a proprietary bio-scaffolding technology, for the treatment of neurodegenerative diseases and neurotrauma. Its programs include spinal cord injury and Parkinson's disease with on-going development efforts in stroke, traumatic brain injury, hearing loss and ALS. The company was founded on September 10, 2015 and is headquartered in London, the United Kingdom. | Director/Board Member | 2019-03-20 |
Former positions of Eliseo Salinas
Companies | Position | End |
---|---|---|
PASSAGE BIO, INC. | Chief Tech/Sci/R&D Officer | 2022-03-17 |
ACADIA PHARMACEUTICALS INC. | Chief Tech/Sci/R&D Officer | 2021-02-28 |
New World Laboratories | Chief Tech/Sci/R&D Officer | 2018-08-31 |
RELMADA THERAPEUTICS, INC. | President | 2015-05-19 |
StemCells, Inc.
StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | Chief Tech/Sci/R&D Officer | 2014-02-20 |
Training of Eliseo Salinas
Universidad de Buenos Aires | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
ACADIA PHARMACEUTICALS INC. | Health Technology |
RELMADA THERAPEUTICS, INC. | Health Technology |
PASSAGE BIO, INC. | Health Technology |
Private companies | 18 |
---|---|
Wyeth Corp.
Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Health Technology |
StemCells, Inc.
StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | Health Technology |
Elan Corp. Plc
Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland. | Health Technology |
Synthélabo SA
Synthélabo SA Pharmaceuticals: OtherHealth Technology Synthelabo was a pharmaceutical company which was focused on cardiovascular disease/thrombosis, disorders of central nervous system, oncology and internal medicine. The company was headquartered in Le Plessis-Robinson, France. | Health Technology |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
Adolor Corp.
Adolor Corp. BiotechnologyHealth Technology Adolor Corp. is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company develops and commercializes of novel opioid receptor-targeted therapeutics designed to maintain or improve pain relief and reduce opioid-related side effects. Its commercial product ENTEREG is a small molecule, peripherally acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics like morphine, on the gastrointestinal tract without interfering with central nervous system and mediated analgesia. The company was founded in 1993 and is headquartered in Exton, PA. | Health Technology |
Shire Acquisition, Inc.
Shire Acquisition, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is the researching, development and marketing of prescription medicines. The Group operations focuses on three therapeutic areas - central nervous system disorders, gastrointestinal and renal diseases. The Group's marketed products for such disorders include ADDERALL and ADDERALL XR, for attention deficit hyperactivity disorder, REMINYL for Alzheimer's, co-marketed with Johnson and Johnson and CARBATROL. for epilepsy. The Group is also developing a range of treatments for ADHD which may treat children, adolescents and adults extending the use of its current brand as well as researching non-scheduled compounds. The Group operates in the United Kingdom, the United States of America, France, Germany, Italy, Spain, Ireland, Canada, the Netherlands and the Cayman Islands. | Health Technology |
Elan Pharmaceuticals, LLC
Elan Pharmaceuticals, LLC Pharmaceuticals: MajorHealth Technology Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA. | Health Technology |
Camp Nine, Inc.
Camp Nine, Inc. Pharmaceuticals: GenericHealth Technology Camp Nine, Inc. operates as a clinical stage biopharmaceutical company. The company through its subsidiary Relmada Therapeutics, Inc. focused on developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. Camp Nine was founded on May 31, 2012 and is headquartered in New York, NY. | Health Technology |
ViroChem Pharma, Inc.
ViroChem Pharma, Inc. Pharmaceuticals: MajorHealth Technology ViroChem Pharma, Inc. provides antiviral drug research and development services. The company provides R&D services on HIV/AIDS and hepatitis C. It was founded on April 8, 2004 and is headquartered in Laval, Canada. | Health Technology |
Université Pierre et Marie Curie | Consumer Services |
Wyeth Research
Wyeth Research Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Wyeth Research discovers and develops platforms encompassing pharmaceuticals. The private company is based in Cambridge, MA. | Commercial Services |
Wyeth-Ayerst Research | |
Relmada Therapeutics, Inc. /Old/
Relmada Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Relmada Therapeutics, Inc. is a holding company, which engages in the development of pharmaceutical drugs for the treatment of acute and chronic pains. It focuses in the developing of chronic pain due to cancer, musculoskeletal disorders, and peripheral neuropathy. The company was founded in 2000 and is headquartered in Blue Bell, PA. | Health Technology |
Phoenixus AG
Phoenixus AG Pharmaceuticals: MajorHealth Technology Phoenixus AG operates as a research-based pharmaceutical company. It develops and commercializes treatments for diseases and conditions with limited or no treatment options. The firm's products include Daraprim and Vecamyl. The company was founded by Martin Shkreli on February 24, 2015 and is headquartered in Baar, Switzerland. | Health Technology |
Vyera Pharmaceuticals LLC
Vyera Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vyera Pharmaceuticals LLC operates as a biopharmaceutical company that focuses on patients with unmet medical needs. Its products include Vecamyl and Daraprim. The firm engages in developing and commercializing treatments for serious diseases and conditions of therapeutic areas. The company was founded by Martin Shkreli in October 10, 2014 and is headquartered in New York, NY. | Health Technology |
Fortuna Fix Ltd.
Fortuna Fix Ltd. Pharmaceuticals: MajorHealth Technology Fortuna Fix Ltd. engages in the regenerative medicine company with a patented direct cell reprogramming technology platform and a proprietary bio-scaffolding technology, for the treatment of neurodegenerative diseases and neurotrauma. Its programs include spinal cord injury and Parkinson's disease with on-going development efforts in stroke, traumatic brain injury, hearing loss and ALS. The company was founded on September 10, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
New World Laboratories |
- Stock Market
- Insiders
- Eliseo Salinas